Drug discovery and development pipelines have been greatly impacted by COVID – some more than others. Technology innovation, remote workforces, decentralized clinical trials and faster drug approval (think of COVID vaccines) have all been on the rise. All the while adhering to rigid regulatory frameworks and maintaining good data management practices.
This certainly makes for a very competitive biotech funding space. We are expected to have more IPOs in 2021 than the record-setting 81 in 2020*, which begs the question: what is in store for drug discovery in the next ten years?
Register for this webinar to hear John Keilty, Venture Partner from Third Rock Ventures and Alok Tayi, PhD, VP of Life Sciences at Egnyte discuss the recent biotechnology trends. They will provide insights and real-world actions that can be taken now to keep pace.
Alok Tayi, PhD, Vice President of Life Sciences, Egnyte
Alok is the Vice President of Life Sciences at Egnyte where he is responsible for building and executing the company’s strategy for the life sciences market segment. Alok works across the organization to verticalize our marketing, sales, product, compliance and account management practices for this domain. Before joining Egnyte, Alok was a Y Combinator-backed entrepreneur and started two vertical software-as-a-service companies. Prior to his career in software, Alok spent over 15 years as a scientist: he took part in postdoctoral work at Harvard University with George Whitesides and has published papers in Nature and Nature Chemistry. Alok holds a PhD from Northwestern University and BS from Cornell University.
John Keilty, Venture Partner, Third Rock Ventures
John Keilty currently works at Third Rock Ventures, where he serves as the general manager of platform operations, responsible for the development and implementation of technology roadmaps for companies across the portfolio. Prior to this role, John was the vice president of information technology and informatics at Infinity Pharmaceuticals, where he owned information systems, software development, computational science, biostatistics, clinical data management and clinical informatics. Before joining Infinity in 2002, John was an early member of Millennium Pharmaceuticals, where he held various roles of increasing responsibility, with broad ownership for the creation, management, implementation and transfer of many of the company’s core genomic technologies. Before Millennium, John worked in the Howard Hughes lab of Michael Green at the University of Massachusetts Medical School, focusing on basic research in transcription and gene splicing. John received his B.A. in biology from Clark University and his M.S. in bioinformatics from Brandeis University.
Who Should Attend?
Personnel involved in the following areas:
- Medical (Biotech/Startup)
- Pharmaco (Pharmacodynamics, Pharmacovigilance, Pharmacokinetics)
- Analytical or Analysis, Data Management and Biostatistics (Director or VP-level)
What You Will Learn
In this webinar, participants will learn about:
- Recent biotechnology trends
- Impacts on the drug discovery and development process
- What’s in store for drug discovery in the next few years
Egnyte is the only secure content platform built specifically for business. With thousands of customers worldwide, in a variety of different vertical markets, Egnyte delivers secure content collaboration, compliant data protection and simple infrastructure modernization; all through a single SaaS platform. Founded in 2007, Egnyte is a privately held company with headquarters in Mountain View, CA, and offices in Raleigh, NC, Spokane, WA, London, and Poland. Investors include Google Ventures, Kleiner Perkins, Caufield & Byers, and Goldman Sachs.